During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation ...

Roche has been leading research into the HER2 pathway for over 30 years and is committed to improving the health, quality of ...

UPPSALA, SE / ACCESS Newswire / May 13, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a ...

Kisqali (ribociclib) given alongside endocrine therapy as adjuvant therapy for patients with stage 2 or 3 hormone receptor-positive, HER2-negative breast cancer reduced patients’ risk for ...

Although there is no certainty that vaginal oestrogen carries no increased risk for breast cancer patients, up to 20% either stop or consider stopping their adjuvant endocrine therapy because it ...

Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S.

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...

It aims to assess if camizestrant improves survival outcomes compared to standard adjuvant endocrine-based therapy for patients who are ER-positive and HER2-negative. The MHRA’s agile regulatory ...

Ovarian cancer, often termed a silent killer, remains underdiagnosed due to vague symptoms and lack of screening. With high ...